CMV-SV40/LTA(RFP, Bla) Lentiviral Particles

CMV-SV40/LTA (RFP, Bla) Lentiviral Particles are high-titer, replication-incompetent viral vectors designed for the robust and stable expression of the Simian Virus 40 Large T Antigen (SV40 LTA) across a wide array of mammalian cell types. These third-generation lentiviral particles utilize the potent human Cytomegalovirus (CMV) immediate-early promoter to drive constitutive high-level transgene expression. To facilitate experimental monitoring and selection, the vector incorporates a dual-marker system consisting of Red Fluorescent Protein (RFP) and a blasticidin (Bla) resistance gene. The RFP reporter allows for non-invasive, real-time visualization of transduction efficiency via fluorescence microscopy or flow cytometry, while the blasticidin marker enables the rapid generation of stable cell lines through antibiotic selection. Engineered for high biosafety and efficiency, these particles ensure the seamless integration of the genetic payload into the host genome, making them a reliable tool for long-term functional studies.

The primary application of these lentiviral particles is cell immortalization, as the SV40 Large T Antigen effectively bypasses replicative senescence by sequestering and inactivating essential tumor suppressors like p53 and the retinoblastoma (Rb) protein family. This allows researchers to transform primary cells into continuous, proliferative cell lines while maintaining many of their original phenotypic characteristics. Beyond immortalization, these particles are extensively used in studies investigating viral oncogenesis, DNA replication, and cell cycle regulation. The inclusion of the RFP and blasticidin markers makes them particularly well-suited for high-throughput screening, lineage tracing, and complex co-transduction experiments where multiple genetic modifications are required. By enabling high-efficiency gene delivery into even hard-to-transfect primary cells, this product serves as a versatile resource for cancer research, drug discovery, and the development of specialized cell models for biotechnological applications.